Thu, Aug 21, 2014, 4:44 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Aradigm Corporation Message Board

  • ndanger2 ndanger2 May 14, 2013 11:12 AM Flag

    Another CF inhale med

    Another CF inhale med company looking good, like what ARDM could be someday, a $9 stock.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • If you want to monitor all the inhalational antibiotics, go to cff DOT org. This is the Cystic Fibrosis Foundation website. Then go to the lefthand menu and drop down to (something like) New Therapies. Then scroll down to antibiotics. There is tobramycin (solution and powder), Cayston, etc., etc. The entire pipeline is pretty inclusive except they do not include Clostin which got a backdoor to CF antibiotics and another one for MRSA (Methacillin Resistant Staph aureus). But there are several that have completed Phase III (Arikace) and some just starting (a BAY amikacin solution). Better choices for patients. But the important point for inhaled cipro is the fact that you can take oral cipro (low toxicity) and inhaled cipro and catch the bacteria in between two bacteriocidal treatment. Right now it is only cipro orally which allows the bacteria on the outside of the "glump" in the lungs to be protected from treatment. If you take cipro orally it comes out with the exudate (the stuff the bacteria is living on) and if you simultaneously inhale cipro, you have the bacteria in an antibiotic vice. Just so you know, I am probably the only veterinarian that since the 1970 have given oral and topical treatment to dog ear infections. I could knock them out in less than 7 days with the "antibiotic vice" method. The only problem it is about twice as expensive and owners did not want to pay. Now people have insurance on doggie Rx.

      Sentiment: Strong Buy

8.90+0.25(+2.89%)Aug 20 3:58 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.